T1	Participants 76 112	patients with chronic kidney disease
T2	Participants 194 229	patients with mild renal impairment
T3	Participants 386 449	patients who underwent percutaneous coronary intervention (PCI)
T4	Participants 494 613	patients enrolled in the Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) trial.
T5	Participants 924 1097	Patients with CrCl <60 ml/min were more likely to be older, women, hypertensive, and have a history of coronary artery bypass surgery, stroke, or peripheral vascular disease
T6	Participants 709 770	(1,755 with CrCl > or =60 ml/min and 289 with CrCl <60 ml/min
T7	Participants 1645 1680	patients with mild renal impairment
